Supply Chain & Manufacturing Taskforce
Where we are today

“Novavax to start shipping COVID-19 vaccines to COVAX program in third quarter” (Reuters, May 6)

“Moderna commits up to 500M vaccine doses to COVAX” (Politico, May 3)

“Covax has reserved 500 million doses of the J&J vaccine” (New York Times, March 12)

Supply and manufacturing challenges remain

“Export controls of input supplies threaten to hinder global vaccine production” (The Economist, April 24)

“The next big COVID-19 bottleneck? A shortage of trained vaccine workers” (Fierce Pharma, April 23)

“Syringe shortage hampers Japan's COVID-19 vaccination roll out” (Reuters, Feb 16)
The Supply Chain & Manufacturing Taskforce has set an impact-ambition along four workstreams

<table>
<thead>
<tr>
<th>Workstream</th>
<th>Aspiration</th>
<th>Convener</th>
</tr>
</thead>
</table>
| **1**     | Immediate COVAX Response  
CEPI: N. Lurie & M. Downham  
Create partnership to enhance visibility on input supplies  
Accelerate export permits/custom clearance for critical SKUs  
Expand fill & finish match making mechanisms | Short-term COVID impact (1-3 months)  
CEPI  
N. Lurie  
M. Downham |
| **2**     | Mid-Term COVAX Response  
CEPI: N. Lurie & M. Downham  
Gavi: D. Maugeais & H. Kettler  
Create overview of global manufacturing capacities  
Better utilize existing capacities, e.g., voluntary tech transfer  
Develop regulatory & manufacturing workforce | Mid-term COVID impact (Until end of 2022)  
CEPI  
N. Lurie  
M. Downham  
Gavi  
D. Maugeais  
H. Kettler |
| **3**     | Long-Term Sustainable Manufacturing  
WHO: M. Friede & R. Long  
BMGF: D. Robinson  
Expand capabilities of existing manufacturers in LMICs: grow existing capabilities and strengthen the know-how of existing manufacturers  
Establish sustainable capacity in regions with no significant capacity | Long-term COVID-19 and beyond impact  
WHO  
M. Friede  
R. Long  
BMGF  
D. Robinson |
| **0**     | Shared fact base / Task Force Coordination Office  
Create aligned supply baseline  
Conduct supply and manufacturing ecosystem mapping  
Maintain an integrated view of funding requirements across workstreams | Enabling baseline of information  
CEPI  
Gavi  
World Health Organization  
UNICEF  
Bill & Melinda Gates Foundation  
Global Health Initiative  
Shared fact base  
Task Force Coordination Office  
N. Lurie  
M. Downham  
D. Maugeais  
H. Kettler  
M. Friede  
R. Long  
D. Robinson |
## Workstream 0: Shared fact base / Task Force Coordination Office

**PRELIMINARY**

<table>
<thead>
<tr>
<th>Initial achievements</th>
<th>Priorities for next weeks</th>
<th>Key milestones going forward</th>
</tr>
</thead>
<tbody>
<tr>
<td>• Launched <em>manufacturing taskforce</em></td>
<td>• Finalize ecosystem mapping and disseminate further</td>
<td>• Develop <em>supply outlook</em> (first version end of May)</td>
</tr>
<tr>
<td>• First draft of <em>ecosystem mapping</em> (~ 30 organizations, 130 ongoing initiatives)</td>
<td>• Ensure <em>taskforce is up and running</em> and whole group convened</td>
<td>• Publish aligned <em>ecosystem mapping</em> (first version end of May)</td>
</tr>
<tr>
<td>• First view of supply data</td>
<td>• Develop <em>supply baseline and test assumptions</em></td>
<td>• Create overview of immediate enabling resources needs (end of May)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Have <em>Taskforce Coordination Office</em> up and running (end of May)</td>
</tr>
</tbody>
</table>

---

Sensitivity: CEPI Internal
## Workstream 1: Immediate COVAX Response

### PRELIMINARY

<table>
<thead>
<tr>
<th>Initial achievements</th>
<th>Priorities for next weeks</th>
<th>Key milestones going forward</th>
</tr>
</thead>
<tbody>
<tr>
<td>• Validated supplier and manufacturer interest in input supply marketplace and detailed marketplace design</td>
<td>• Finalize the charter/terms of participation to ensure legal compliance and confidentiality</td>
<td>• <strong>Launch</strong> initial input supply marketplace <em>(June)</em></td>
</tr>
<tr>
<td>• Identified first set of pain points and solutions for free flow of goods</td>
<td>• <strong>Onboard partners</strong> to marketplace and prepare for launch</td>
<td>• <strong>Launch</strong> free flow of goods interventions <em>(June)</em></td>
</tr>
<tr>
<td>• Identified key intervention areas for improving Fill &amp; Finish matchmaking</td>
<td>• <strong>Detail list of critical SKUs</strong> and export permit acceleration solutions</td>
<td>• <strong>Launch</strong> of Fill &amp; Finish matchmaking interventions <em>(June)</em></td>
</tr>
<tr>
<td>• Engaged key governments and stakeholders (e.g., USG, EC)</td>
<td>• <strong>Implement intervention</strong> areas identified</td>
<td></td>
</tr>
</tbody>
</table>
### Workstream 2: Mid-Term COVAX Response

**Initial achievements**

- Identified and accessed key sources of data for existing capacity mapping
- Started framing of key challenge areas & potential solutions
- Identified interdependencies with other taskforce workstreams

**Priorities for next weeks**

- Continue data collection/consolidation for mapping
- Finalize assessment and mapping of priority problems and potential mid-term solutions
- Develop draft solutions in partnership with manufacturers based on the identified pain points

**Key milestones going forward**

- Finalize pain points and capacity mapping and share with key partners *(June)*
- **Share proposed solutions/COVAX value proposition** to address mid-term capacity challenges with key partners *(June)*
Workstream 3: Long-Term Sustainable Manufacturing

PRELIMINARY

Initial achievements

- **Initial EOI** issued by WHO for mRNA hub
- Aligned on **3 design choices** for expanding & creating vaccine manufacturing in LMICs
- Defined initial **program structure** (working groups, deliverables, timeline) for detail design and implementation
- Shared **draft concept note** for input from partners

Priorities for next weeks

- Conduct info call on **concept note**, address feedback and confirm optimal go-forward **design model**
- Complete high-level **costing estimate**
- Refine **working groups** and identify participants/leads
- Continue to synthesize **EOI responses & evaluation**

Key milestones going forward (see details on following selected WS3 output pages)

- **Design options** developed and evaluated, incl. high-level costing estimate (**end of May**)
- Target tech & IP landscape initiated, expert panel defined (**end of May**)
- **Concept note** for design phase released (**end of May**)
- **Roadmap for next EOLs** completed (**end of May**)
- **Workstreams launched & detailed planning** of chosen design option conducted (**end of June-end of 2022**)
- **Plans translated into action** and execution initialized (**2022 and beyond**)
WS3 selected output – We defined 3 discrete phases of work for our workstream

**Design**
*Current phase*

- Develop & evaluate design options
- Define program working groups, key milestones and timeline
- Publish concept note v1
- Process EOI responses & prepare for additional EOIs
- Engage with stakeholders for input; identify working group participants
- Conduct initial IP landscaping
- Size high-level costs for subsequent phases

**Detailed Design & Pilot**

- Select technology for transfer
- Design hub and potential affiliate network, select locations
- Develop plan for regulatory & workforce strengthening
- Define hub & recipient governance model
- Refine costing estimates, mobilize funds
- Continue engagement with Member States & other key stakeholders for input
- Issue subsequent EOIs

**Build & Implement**

- Complete facility design & initiate build
- Negotiate & manage any necessary licenses
- Publish normative policy guidance
- Prepare programs for regulatory & workforce strengthening
- Launch initial transfer of selected technology to hub

Now to end of May
- Develop concept & design options, define program structure

June to end of 2021
- Launch workstreams & conduct detailed planning of chosen design option

2022 and beyond
- Translate plans to action, initiate execution

Key activities

+ other partners as needed to support specific workstreams across build & implementation

WS 3 leads

Note: Exact timeline TBC

Sensitivity: CEPI Internal
WS3 selected output – Vision:
Once design Model is defined, we will embark in a multi-year journey to establish the LMIC network

Release concept note
Collect EOI across techs (mRNA, viral, protein)

Define criteria, select hub & tech transfer recipients

Design sites, develop business plans

See status on next page

Expand or build sites for 1-2 recipients

Begin the hub build

Secure funding

Tech transfer to initial recipients

Expand hub for additional technologies

Train recipients and enable Vaccine production

Expand recipients to additional technologies

New vaccines in LMICs

Today Rest of 2021 2022 Starting in 2023-4
WS3 selected output – Zoom: Currently processing mRNA EOI responses and identifying possible Donors/Recipients

42 responses to date spanning across many regions - preliminary

Current activities
- Replied to all respondents to acknowledge submission
- Scheduling calls with promising respondents for additional details
- Reaching out to other entities / countries to complement initial responses
- Defining initial criteria to assess fit with overall network and began donors/ recipients assessment

Path forward
- Refine selection of donors/ recipients
- Synthesize findings & recommendations
- Prepare for & launch EOIs for other techs in late summer

As of 05.10

Tech Donor / Possible Hub 15
Tech Recipient 19
Other (request for information, relay of the initiative, etc.) 8

Including responses from entities based in:
- USA
- China
- Italy
- UK
- India
- South Africa
- Taiwan
- Senegal
- Argentina
- Brazil
- Senegal
- South Korea
- China
- Vietnam
- Bangladesh
- Peru
- Argentina
- India
- Uganda
- Thailand
- Pakistan
- Indonesia
- Nigeria
- Nicaragua
- China
- Italy
- India
Thank you